|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GET4 |
Gene summary for GET4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GET4 | Gene ID | 51608 |
| Gene name | guided entry of tail-anchored proteins factor 4 | |
| Gene Alias | C7orf20 | |
| Cytomap | 7p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q7L5D6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51608 | GET4 | LZE2T | Human | Esophagus | ESCC | 4.73e-03 | 6.08e-01 | 0.082 |
| 51608 | GET4 | LZE4T | Human | Esophagus | ESCC | 2.18e-06 | 2.13e-01 | 0.0811 |
| 51608 | GET4 | LZE20T | Human | Esophagus | ESCC | 5.57e-10 | 2.92e-01 | 0.0662 |
| 51608 | GET4 | LZE21D1 | Human | Esophagus | HGIN | 5.38e-03 | 2.63e-01 | 0.0632 |
| 51608 | GET4 | LZE22D1 | Human | Esophagus | HGIN | 3.26e-02 | 1.43e-01 | 0.0595 |
| 51608 | GET4 | LZE22T | Human | Esophagus | ESCC | 8.47e-11 | 6.95e-01 | 0.068 |
| 51608 | GET4 | LZE24T | Human | Esophagus | ESCC | 7.06e-21 | 4.62e-01 | 0.0596 |
| 51608 | GET4 | LZE22D3 | Human | Esophagus | HGIN | 1.73e-02 | 5.15e-01 | 0.0653 |
| 51608 | GET4 | LZE21T | Human | Esophagus | ESCC | 1.57e-07 | 4.29e-01 | 0.0655 |
| 51608 | GET4 | P1T-E | Human | Esophagus | ESCC | 2.01e-24 | 8.26e-01 | 0.0875 |
| 51608 | GET4 | P2T-E | Human | Esophagus | ESCC | 1.49e-39 | 7.41e-01 | 0.1177 |
| 51608 | GET4 | P4T-E | Human | Esophagus | ESCC | 1.99e-47 | 9.81e-01 | 0.1323 |
| 51608 | GET4 | P5T-E | Human | Esophagus | ESCC | 1.92e-37 | 6.83e-01 | 0.1327 |
| 51608 | GET4 | P8T-E | Human | Esophagus | ESCC | 2.28e-35 | 6.41e-01 | 0.0889 |
| 51608 | GET4 | P9T-E | Human | Esophagus | ESCC | 8.50e-30 | 6.27e-01 | 0.1131 |
| 51608 | GET4 | P10T-E | Human | Esophagus | ESCC | 1.80e-47 | 7.59e-01 | 0.116 |
| 51608 | GET4 | P11T-E | Human | Esophagus | ESCC | 1.20e-27 | 1.01e+00 | 0.1426 |
| 51608 | GET4 | P12T-E | Human | Esophagus | ESCC | 6.31e-57 | 9.11e-01 | 0.1122 |
| 51608 | GET4 | P15T-E | Human | Esophagus | ESCC | 1.30e-46 | 8.30e-01 | 0.1149 |
| 51608 | GET4 | P16T-E | Human | Esophagus | ESCC | 2.41e-29 | 5.61e-01 | 0.1153 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
| GO:003164727 | Esophagus | HGIN | regulation of protein stability | 96/2587 | 298/18723 | 2.21e-16 | 5.76e-14 | 96 |
| GO:003497625 | Esophagus | HGIN | response to endoplasmic reticulum stress | 81/2587 | 256/18723 | 1.47e-13 | 2.32e-11 | 81 |
| GO:009015020 | Esophagus | HGIN | establishment of protein localization to membrane | 67/2587 | 260/18723 | 1.96e-07 | 9.57e-06 | 67 |
| GO:00512057 | Esophagus | HGIN | protein insertion into membrane | 21/2587 | 57/18723 | 1.16e-05 | 3.29e-04 | 21 |
| GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
| GO:004518523 | Esophagus | HGIN | maintenance of protein location | 28/2587 | 94/18723 | 4.52e-05 | 1.09e-03 | 28 |
| GO:00450483 | Esophagus | HGIN | protein insertion into ER membrane | 10/2587 | 22/18723 | 3.28e-04 | 5.46e-03 | 10 |
| GO:00365036 | Esophagus | HGIN | ERAD pathway | 27/2587 | 107/18723 | 1.15e-03 | 1.39e-02 | 27 |
| GO:00512205 | Esophagus | HGIN | cytoplasmic sequestering of protein | 9/2587 | 22/18723 | 1.64e-03 | 1.82e-02 | 9 |
| GO:00070295 | Esophagus | HGIN | endoplasmic reticulum organization | 22/2587 | 87/18723 | 3.07e-03 | 2.90e-02 | 22 |
| GO:00718163 | Esophagus | HGIN | tail-anchored membrane protein insertion into ER membrane | 7/2587 | 17/18723 | 5.21e-03 | 4.30e-02 | 7 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:003650315 | Esophagus | ESCC | ERAD pathway | 82/8552 | 107/18723 | 5.80e-11 | 1.84e-09 | 82 |
| GO:0045185111 | Esophagus | ESCC | maintenance of protein location | 71/8552 | 94/18723 | 3.41e-09 | 7.24e-08 | 71 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:000702914 | Esophagus | ESCC | endoplasmic reticulum organization | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GET4 | SNV | Missense_Mutation | c.548C>T | p.Ser183Phe | p.S183F | Q7L5D6 | protein_coding | tolerated(0.08) | possibly_damaging(0.559) | TCGA-A2-A0YT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD | |
| GET4 | SNV | Missense_Mutation | c.911G>C | p.Ser304Thr | p.S304T | Q7L5D6 | protein_coding | tolerated(0.14) | benign(0.299) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
| GET4 | SNV | Missense_Mutation | c.542A>G | p.Glu181Gly | p.E181G | Q7L5D6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GET4 | SNV | Missense_Mutation | rs759801442 | c.187N>T | p.Arg63Trp | p.R63W | Q7L5D6 | protein_coding | deleterious(0.04) | probably_damaging(0.978) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GET4 | SNV | Missense_Mutation | rs754748449 | c.685G>A | p.Gly229Arg | p.G229R | Q7L5D6 | protein_coding | deleterious(0.01) | possibly_damaging(0.876) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GET4 | SNV | Missense_Mutation | c.254N>C | p.Leu85Ser | p.L85S | Q7L5D6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-CL-5917-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| GET4 | SNV | Missense_Mutation | novel | c.223N>G | p.Ser75Gly | p.S75G | Q7L5D6 | protein_coding | deleterious(0.04) | possibly_damaging(0.747) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GET4 | SNV | Missense_Mutation | novel | c.608N>G | p.Phe203Cys | p.F203C | Q7L5D6 | protein_coding | tolerated(0.19) | possibly_damaging(0.81) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GET4 | SNV | Missense_Mutation | novel | c.493C>A | p.His165Asn | p.H165N | Q7L5D6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GET4 | SNV | Missense_Mutation | novel | c.776N>A | p.Cys259Tyr | p.C259Y | Q7L5D6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |